EUR 0.29
(-5.84%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 840.45 Thousand EUR | -88.11% |
2022 | 4.34 Million EUR | -5.07% |
2021 | 4.57 Million EUR | 17.28% |
2020 | 3.89 Million EUR | -87.64% |
2019 | 31.54 Million EUR | 11.58% |
2018 | 28.27 Million EUR | 701.0% |
2017 | 3.52 Million EUR | 7.14% |
2016 | 3.29 Million EUR | 41.63% |
2015 | 2.32 Million EUR | 1.81% |
2014 | 2.28 Million EUR | 107.38% |
2013 | 1.1 Million EUR | -34.99% |
2012 | 1.69 Million EUR | 56.43% |
2011 | 1.08 Million EUR | 23.19% |
2010 | 879.46 Thousand EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 FY | 516.09 Thousand EUR | -88.11% |
2023 Q2 | -813.27 Thousand EUR | 0.0% |
2023 Q3 | 1.21 Million EUR | 249.42% |
2023 Q1 | -813.27 Thousand EUR | -177.76% |
2023 Q4 | 1.21 Million EUR | 0.0% |
2022 FY | 4.34 Million EUR | -5.07% |
2022 Q4 | 1.04 Million EUR | 0.0% |
2021 FY | 4.57 Million EUR | 17.28% |
2020 FY | 3.89 Million EUR | -87.64% |
2019 FY | 31.54 Million EUR | 11.58% |
2018 FY | 28.27 Million EUR | 701.0% |
2017 FY | 3.52 Million EUR | 7.14% |
2016 FY | 3.29 Million EUR | 41.63% |
2015 FY | 2.32 Million EUR | 1.81% |
2014 FY | 2.28 Million EUR | 107.38% |
2013 FY | 1.1 Million EUR | -34.99% |
2012 FY | 1.69 Million EUR | 56.43% |
2011 FY | 1.08 Million EUR | 23.19% |
2010 FY | 879.46 Thousand EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Atrys Health, S.A. | 143.61 Million EUR | 99.415% |
Oryzon Genomics S.A. | 18.49 Million EUR | 95.456% |
Pharma Mar, S.A. | 152.36 Million EUR | 99.448% |
Laboratorios Farmaceuticos Rovi, S.A. | 263.09 Million EUR | 99.681% |